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Summary
INTRODUCTION
 Reproducibility of laboratory results and performance of diagnostic tools form major part 
of quality assurance in diagnosis. This is key to care of patients with tuberculosis (TB) in Kenya. 
However, to our knowledge, no study has documented comparison of reproducibility of laboratory 
results and performance of these TB diagnostic tools in different geographical settings. 
OBJECTIVE
 To determine reproducibility of laboratory results and performance of ZN and new 
TB diagnostic tools in different geographical settings in the East Africa Public Health laboratories 
Networking Project - Operational Research (EAPHLNP-OR) Tuberclosis(TB) study in Kenya. 
Equally it was to evaluate the impact of new tuberculosis diagnostics on patient's health outcomes 
in Kenya. 
METHODOLOGY
 A cross-sectional study was conducted between February 2013 and October 2016. People 
presumed to have TB  aged 18 years and above were enrolled in nine selected public health facilities 
in Busia, Kisii-Keroka, Kitale, Lamu Machakos, Malindi, Nyahururu, Olololunga-Narok and 
Wajir and selected to participate in that EAPHLNP-OR TB project. Spot and morning sputum 
specimens were collected from participants presenting at each of the nine health facilities on two 
consecutive days. A total of 5715 sputum specimens were collected from all the study sites.
 
 A proportion of the specimen at each site was aseptically processed for Ziehl Neelsen 
(ZN), Flourescence Microscopy (FM) and GeneXpert. The remaining specimen portion was triple 
packaged and shipped to the TB research laboratory at the Kenya Medical Research Institute 
(KEMRI), in Nairobi.  
 Processing using the three tests including Lowenstein Jensen (LJ) culture according to 
standard procedures was done at KEMRI in Nairobi. The laboratory personnel were blinded of 
the previous study site results. Data processing was done using MySQL and IBM SPSS version 24 
software. Reproducibility of laboratory results where the specimen was the unit of analysis, was 
determined by Kappa values on homogenous specimens and performance by diagnostic values 
(sensitivity, specificity, positive/ negative predictive values). 
 Results from the same specimens at the study sites were compared with those from KEMRI 
research laboratory LJ culture was used as a gold standard to evaluate performance, where the 
patient was the unit of analysis.
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RESULTS 
 Generally, excellent Kappa values for GeneXpert (0.855 (95%   CI : 0.834 - 0.876 ), 
n  =  660) was significantly higher than ZN microscopy   ( 0.721   (  95%     CI  : 0.708  -  0.734 ), 
n  = 3252). FM Kappa value  (0.749  (95%   CI : 0.736 - 0.762 ),  n = 2816 ) indicated substantial 
agreement. Specific results for the three diagnostic tools varied across the sites for microscopy 
but were not significantly different for GeneXpert. 
 Cumulatively, there was marginal significant incremental sensitivity of microscopy at 
the study sites ZN (69.9% (95% CI: 64.3 - 75.5); n = 259) and FM (76.7% (95% CI: 71.1 - 82.3) 
; n = 219) than at KEMRI ZN (68.7% (95% CI: 63.1-74.4); n = 259) and FM (70.8% (95% 
CI:64.8 - 76.8)%; n = 219). 
 Apparently, the sensitivity of GeneXpert at the study sites (81.4% (95% CI:71.4 - 91.3) 
; n = 59) was not significantly different from that of GeneXpert at KEMRI (81.4% 
(95% CI: 71.4 - 91.3); n = 59). Specificity of GeneXpert at the site was not significantly 
different to that of  KEMRI but significantly lower than microscopy both at site and 
KEMRI. Microscopy results varied across specific study sites but not significantly different for 
GeneXpert. A similar pattern was observed for positive / negative predictive values.
CONCLUSION
  Results generated by GeneXpert MTB/RIF indicated excellent reproducibility but there 
was no significant difference in performance, regardless of geographical setting in Kenya.   This 
suggests that under ideal conditions GeneXpert MTB/RIF is a reliable diagnostic tool irrespective 
of the facility setting. 
 Due to higher specificity and positive/negative predictive values of microscopy to 
GeneXpert, microscopy could compliment GeneXpert in detection of mycobacteria, especially in 
settings with inadequate capacity, including infrastructure, human resource and high workload. 
There is need for continuous training in microscopy to enhance reproducibility of laboratory 
results and performance.
[Afr. J. Health Sci.  2019 32(4) : 7 - 22]
Introduction 
 Reproducibility is the ability of an entire 
experiment or study to be duplicated, either by the same 
researcher or by someone else working independently. 
 A particular experimentally obtained value 
is said to be reproducible if there is a high degree of 
agreement between measurements and observations 
conducted on replicate specimens in different locations 
by different people-that is, if the experimental value is 
found to have a high precision. (ASTM International, 
ASTM E177-2014).[1] 
 Reproducibility of laboratory results and 
performance of diagnostic tools form a major part of 
quality assurance in laboratory diagnosis, which is key 
in patient management. 
 Performance of a diagnostic tool results in 
diagnostic values (Sensitivity, Specificity, PPV and 
NPV) generated using a gold standard. In medical 
diagnosis, test sensitivity is the ability of a test to 
correctly identify those with the disease (True Positive 
Rate), whereas test specificity is the ability of the test 
to correctly identify those without the disease True 
Negative Rate). 
 Quality assured diagnosis is key to care of 
patients with tuberculosis (TB). Research on new TB 
diagnostic tools and evaluation on their performance 
has taken centre stage nowdays.
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 In Kenya, performance of such tools including 
Led Emitted Diode fluorescent microscopy (LED-FM) 
and Xpert MTB/ RIF® (GeneXpert), have recently been 
documented. Reproducibility of laboratory results and 
performance of diagnostic tools form major part of 
quality assurance in diagnosis of tuberculosis (TB)  in 
patients.
  Regardless, of our knowledge, no study has 
documented comparison of reproducibility of laboratory 
results and performance of these TB diagnostic tools in 
different geographical settings.
Objective
 To determine reproducibility of laboratory 
results and performance of ZN and new TB diagnostic 
tools in different geographical settings in the East 
Africa Public Health Laboratories Networking Project-




 A cross sectional design involving deter-
mination of the reliability and diagnostic test values of 
ZN and new TB diagnostics, LED-FM and GeneXpert.
Study Area
 Nine study sites; Busia, Kisii-Keroka, Kitale, 
Lamu Machakos, Malindi, Nyahururu, Olololunga-
Narok and Wajir were selected to participate in the main 
EAPHLN-OR TB project. The main objective was to 
evaluate the impact of new tuberculosis diagnostics on 
patients' health outcomes in Kenya.
Study Population
 A cross-sectional study was conducted between 
February 2013 and October 2016. People presumed to 
have TB, aged 18 years and above were enrolled at the 
nine selected public health facilities. 
 A total of  5715 sputum specimens were 
collected from all the study sites. Consenting age was 
eighteen (18) years and above to be enrolled in the public 
health facilities.
 Spot and morning sputum specimens were 
collected from participants presenting at each of the 
nine health facilities on two consecutive days. 
 At each site, a proportion of each specimen 
was aseptically processed for ZN, FM and GeneXpert 
(where available). The remaining portion of the 
specimen was triple packaged and shipped to the TB 
research laboratory at the Kenya Medical Research 
Institute (KEMRI), Nairobi. Here, they were processed 
using the three tests including Lowensen Jensen (LJ) 
culture in accordance with standard procedures. 
 
 The laboratory personnel at KEMRI, were 
unaware of the study sites results. Data processing was 
done using  MySQL and IBM SPSS version 24 software. 
 Reproducibility of laboratory results where 
the specimen was the unit of analysis  was determined 
by Kappa values on homogenous specimens and 
performance by diagnostic values (Sensitivity, 
Specificity, Positive / Negative Predictive Values). 
 Results from the same specimens at the study 
sites were compared with those from KEMRI research 
laboratory. LJ culture was used as a gold standard to 
evaluate performance, where the patient was the unit of 
analysis.
Results
 Figure 1 presents patients flow from enrolment 
for sputum sample analysis in the laboratory. 
 A Total of 3075 people presumed to have TB 
were enrolled between February 2013 and October 
2016 at all the study sites. Of these, 2928(95.2%) 
respondents produced specimens that were 
accepted for analysis based on a set criterion. 
A total of 5715 specimens were processed as below:
2782 / 2928    (95.0%) Patients had both (spot and  
           morning specimens. 
146 / 2928       (5.0%) Patients produced one   
   sputum  specimen 
   (105 spot, 41 morning). 
 The specimens were processed at the study sites 
using Ziehl Neelsen (ZN), LED Fluorescent (LED-FM) 
microscopy and GeneXpert, and at KEMRI using ZN, 
LED-FM, GeneXpert and LJ solid culture.
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Total number of patients with 
presumptive TB enrolled
N=3075
 2928 patients with accepted 
sputum samples
5715 sputum samples 
- 2782 with both (spot (S) & morning (M)
- 146 with one (105 S, 41 M)
ZN: 2768 patients (97.5%)
- 5407 Sputum Processed
- 2639 with both (S & M) 
- 129 with one (105 S, 24 M)
FM: 2374 patients (81.1%)
- 4618 Sputum Processed
- 2244 with both (S & M)
- 130 with one (102 S, 28 
GXpert: 963 patients (32.9%)
- 1716 Sputum Processed
- 753 with both (S & M)
- 210 with one (191 S, 19 
ZN: 2578 patients (88.0%)
- 4635 Sputum Processed
- 2057 with both (S & M)
- 521 with one (243 S, 278 M)
FM: 2622 patients (89.5%)
- 4745 Sputum Processed
- 2123 with both (S & M)
- 499 with one (230 S, 269 M)
GXpt: 1843 patients (62.9%)
- 2883 Sputum Processed
- 1040 with both (S & M)
- 803 with one (399 S, 404 
LJ Cult: 2532 patients (86.5%)
- 4426 Sputum Processed
- 1894 with both (S & M)
- 638 with one (314 S, 324 
Processed at Study sites Laboratories
Figure 1:    Patients Flow From Enrolment To Sputum Sample Analysis In The Laboratory
Processed at KEMRI Research Laboratory
147 patients without sputum samples
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 (Table 1) presents selected demographic 
characteristics of all the enrolled participants. A total of 
3075 people presumed to have TB were enrolled into the 
study.   
 Selected demographic characteristics of all 
the enrolled participants are presented in (Table 2) 
The proportion of male (47.6%) to female (42.9%) 
was visible with more male than female. Mean age 
of the people presumed to have TB was 39 (+16.5SD) 
ranging between 18 and 98 years. Majority of the study 
participants (43.6%) were in the age group of between 
20 and 39 years.
Table 1: Enrolled People Presumed To Have TB Per Site and Their Selected Demographic Characteristics
Characteristics n = 3075 %













Not documented 290 9.5
Age in years  
<20 years 213 6.9
20 - 29 years 630 20.5
30 - 39 years 709 23.1
40 - 49 years 456 14.8
50 - 59 years 290 9.4
60 - 69 years 208 6.8
70 - 79 years 181 5.9
80 and above 388 12.6
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 Table 2 shows the prevalence of tuberculosis 
among the study participants (with both spot and 
morning samples) according to different diagnostic 
tools and the testing site. 
  
 At the study sites laboratories, GeneXpert 
detected more participants as TB positive (23.9%) 
followed by FM (16.8%) and ZN (15.6%). Similarly, 
analysis at the KEMRI research laboratory confirmed 
that, GeneXpert detected more study participants 
as TB positive (23.3%) followed by ZN (16.5%) and 
FM (15.8%). The prevalence of TB was comparable 
according to the microscopy diagnostic tools (ZN and 
FM) but significantly high according to GeneXpert at 
both study sites and KEMRI research laboratories. 
 The prevalence of TB by LJ culture was 
significantly lower than GeneXpert at both study sites 
and at the KEMRI laboratory.
Table 2: Prevalence Of Tuberculosis Among The Study Participants According To Different Diagnostic Tools (With  
 Both Spot and Morning Samples)
Point Of Analysis Diagnostic Tool Prevalence (95% CI)
Study Sites 
Laboratories
ZN Microscopy (n=1626) 15.6(13.8-17.4)




ZN Microscopy (n=1626) 16.5(14.7-18.3)
FM Microscopy (n=1408) 15.8(13.9-17.7)
GeneXpert (n=330) 23.3(18.7-27.9)
Culture: LJ (n=1728) 15.6(13.9-17.3)
 Reproducibility of results for different TB 
diagnostic tools between study sites and KEMRI 
research laboratory was determined as presented in 
Table 3. Generally, excellent Kappa value for GeneXpert 
(0.855(95%CI: 0.834-0.876), n=660) was significantly 
higher than ZN microscopy (0.721(95%CI: 0.708-0.734), 
n=3252). FM Kappa value (0.749(95%CI: 0.736-0.762), 
n=2816) indicated substantial agreement. Results varied 
across the sites for both ZN and FM microscopy but 
were not significantly different for GeneXpert.
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Positive 345 125 470
0.721(0.708-0.734)
Negative 93 2689 2782










Positive 324 116 440
0.749(0.736-0.762)
Negative 61 2315 2376











Positive 130 19 149 0.855(0.834-0.876)
Negative 14 497 511
Total 144 516 660
Key:     n = Number,  N = Total number
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 Table 4 shows reproducibility of ZN results for 
different TB diagnostic tools between individual study 
sites and KEMRI research laboratory. Reproducibility 
of ZN microscopy results varied significantly across 
some sites, ranging from Kappa value = 0.308 (95% 
CI: 0.215 - 0.401) in Lamu to Kappa value = 0.830 (95% 
CI: 0.779 - 0.881) in Nyahururu.
 Key: *Sample size inadequate,   L = Lower limit,   U = Upper limit,   n =Number,   N = Total number
Table 4: Reproducibility Of ZN Results For Different TB Diagnostic Tools Between Study Sites and KEMRI Research 
 Laboratory
ZN KEMRI 95% CI







Busia ZN site Positive 63 20 83
0.693 0.663 0.723
Negative 25 490 515
Total 88 510 598
Kitale ZN site Positive 86 42 128
0.714 0.688 0.740
Negative 13 593 606
Total 99 635 734
Machakos ZN site Positive 34 9 43
0.756 0.714 0.798
Negative 8 185 193
Total 42 194 236
Malindi ZN site Positive 95 30 125
0.747 0.722 0.772
Negative 25 938 963
Total 120 968 1088
Wajir ZN site Positive 26 14 40
0.669 0.624 0.714
Negative 6 176 182
Total 32 190 222
Kisii ZN site Positive 14 2 16
0.773 0.710 0.836
Negative 5 125 130
Total 19 127 146
Nyahururu ZN site Positive 23 2 25
0.830 0.779 0.881
Negative 5 88 93
Total 28 90 118
Narok * ZN site Positive 3 5 8
0.347 0.288 0.406
Negative 4 80 84
Total 7 85 92*
Lamu * ZN site Positive 1 1 2
0.308 0.215 0.401
Negative 2 14 16
Total 3 15 18*
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 Table 5 shows reproducibility of FM results 
for different TB diagnostic tools between study sites 
and KEMRI research laboratory. Reproducibility of 
FM results was significantly different across some 
study sites, ranging from Kappa value = 0.667 (95% 
Table 5: Reproducibility Of FM Results Between Study Sites and KEMRI Research Laboratory 
FM KEMRI 95% CI





Busia FM site Positive 63 27 90
0.720 0.690 0.750
Negative 13 493 506
Total 76 520 596
Kitale FM site Positive 77 37 114
0.727 0.699 0.755
Negative 8 448 456
Total 85 485 570
Machakos FM site Positive 41 8 49
0.793 0.754 0.832
Negative 8 177 185
Total 49 185 234
Malindi FM site Positive 103 34 137
0.764 0.740 0.788
Negative 20 933 953
Total 123 967 1090
Wajir * FM site Positive 0 2 2
-0.200 -0.229 -0.171
Negative 1 5 6
Total 1 7 8*
Kisii FM site Positive 12 6 18
0.667 0.602 0.732
Negative 4 122 126
Total 16 128 144
Nyahururu FM site Positive 26 2 28
0.836 0.789 0.883
Negative 6 124 130
Total 32 126 158
Lamu* FM site Positive 2 0 2
0.765 0.596 0.934
Negative 1 13 14
Total 3 13 16*
CI: 0.602 -  0.732) in Kisii to Kappa value = 0.836 
(95% CI: 0.789 - 0.883) in Nyahururu. The kappa 
value on results for samples from Wajir was negative 
(-0.200 (95%   CI: - 0.229 to - 0.171). 
Key: *Sample size inadequate,   L = Lower limit,   U = Upper limit,   n =Number,   N = Total number
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 Table 6: shows reproducibility of GeneXpert 
results between study sites and KEMRI research 
laboratory. Reproducibility of GeneXpert results on 
samples from Wajir (Kappa value = 0.614 (95% CI: 
Table 6: Reproducibility Of GeneXpert Results Between Study Sites and KEMRI Research Laboratory.
0.506-0.722)) was significantly lower than other study 
sites, ranging from Kappa value = 0.871 (95% CI: 
0.829 - 0.912) in Kisii to Kappa value = 0.895 (95% 
CI: 0.831 - 0.959) in Machakos.
GeneXpert KEMRI 95% CI
Study site Diagnostic Tool Positive Negative Total Kappa value L U
Busia GeneXpert 
site Positive 31 4 35
0.871 0.829 0.913
Negative 3 124 127
Total 34 128 162
Kitale GeneXpert 
site Positive 79 12 91
0.859 0.832 0.886
Negative 7 270 277
Total 86 282 368
Machakos* GeneXpert 
site Positive 12 0 12
0.895 0.831 0.959
Negative 2 34 36
Total 14 34 48*
Malindi* GeneXpert 
site Positive 4 1 5
0.874 0.766 0.982
Negative 0 33 33
Total 4 34 38*
Wajir* GeneXpert 
site Positive 4 2 6
0.614 0.506 0.722
Negative 2 36 38
Total 6 38 44*
Key: *Sample size inadequate,   L = Lower limit,   U = Upper limit,   n =Number,   N = Total number
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 Table 7 shows the performance of different 
TB diagnostic tools at study sites and KEMRI research 
laboratory. 
 Cumulatively, there was marginal significant 
incremental sensitivity of microscopy at the study sites 
ZN (69.9% (95% CI : 64.3 - 75.5) % ; n = 259) and FM 
(76.7% (CI: 71.1 - 82.3) %; n = 219) than at KEMRI ZN 
(69.9% (CI: 64.3-75.5) %; n = 259) and FM (70.8% (95% 
CI:  64.8 - 76.8 ) % ; n = 219). 
 However, the sensitivity of GeneXpert at the 





(95% CI) n NPVSpec (95% CI) n
PPV
Spec
(95% CI) n NPVSpec (95% CI)
Total
N
ZN sites 259 69.9 64.3 75.5 1367 94.7 93.5 95.9 253 71.5 66.0 77.1 1373 94.3 93.1 95.5 1626
ZN KEMRI 259 68.7 63.1 74.4 1367 93.3 92.0 94.7 269 66.2 60.5 71.8 1357 94.0 92.8 95.3 1626
FM sites 219 76.7 71.1 82.3 1189 94.2 92.9 95.5 237 70.9 65.1 76.7 1171 95.6 94.5 96.8 1408
FM KEMRI 219 70.8 64.8 76.8 1189 94.4 93.1 95.7 222 69.8 63.8 75.9 1186 94.6 93.3 95.9 1408
GeneXpert 
sites 59 81.4 71.4 91.3 271 88.6 84.8 92.4 79 60.8 50.0 71.5 251 95.6 93.1 98.2 330
GeneXpert 
KEMRI 59 81.4 71.4 91.3 271 89.3 85.6 93.0 77 62.3 51.5 73.2 253 95.7 93.1 98.2 330
Key: 95%   CI: Confidence Interval,   PPV: Positive Predictive Value,     Sen: Sensitivity,      Spec: Specificity,     
                  N:  Total number              NPV: Negative Predictive Value,    n:     Number,          
 Table 8 shows performance of ZN at study sites 
and KEMRI laboratory. Sensitivity of ZN microscopy 
at the satellite sites ranged from 50.0%  (95% CI:  26.9 
- 73.1) % in Wajir to 78.8%  (95%   CI: 71.4 - 86.2) % in 
Kitale.   
 Specificity was generally not statistically 
significantly different within the study sites. The lowest 
observed in Wajir (84.8%  (95%   CI: 79.9 -  89.7) %). 
 Sensitivity of ZN microscopy at non-satellite 
site ranged from;-
 Narok:           40.0%  (95%    CI:   9.6  - 70.4) % 
    to
 Nyahururu:    90.9%  (95%  CI: 78.9 - 100.0) %  
 Specificity was generally not statistically 
significantly different within the study sites. The 
lowest was observed in Kisii - Keroka (94.4%  (95% 
CI:   90.3 - 98.4) %). 
 However, due to the small number of enrolled 
patients, especially in Lamu, sensitivity and specificity 
of ZN microscopy was estimated with wider confidence 
intervals. 
 Therefore, with reduced precision apart from 
Kitale, where the sensitivity of ZN is significantly 
higher than at KEMRI, the reproducibility of ZN was 
comparable with the study sites and KEMRI.
was not statistically significantly different from that of 
GeneXpert at KEMRI (81.4%  (95%    CI :  71.4 - 91.3)% 
; n = 59). 
 Specificity of GeneXpert at the site was not 
statistically significantly different from that at KEMRI 
but lower than that of Microscopy both at site and 
KEMRI. 
 Microscopy results varied across specific study 
sites but not statistically significantly different for 
GeneXpert. A similar pattern was observed for positive/ 
negative predictive values.
Table 7: Performance Of Different TB Diagnostic Tools At Study Sites and KEMRI Research Laboratory 
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 Table 9 shows performance of FM at study 
sites and KEMRI laboratory. Sensitivity of FM 
Microscopy at study sites ranged from 68.2% (95% 
CI: 58.5 - 77.9) % in Kitale to 87.5% (95%  CI: 80.6 - 
94.4) % in Kitale.
 Specificity was generally not statistically 
significantly different within the study sites. The lowest 
observed in Machakos (89.2%(95% CI:84.9-93.6) %). 
Sensitivity of FM Microscopy at the study sites within 
non-satellite sites ranged from 45.5% (95% CI:24.6-
Table 9: Performance Of FM Microscopy At Study Sites and Kemri Research Laboratory.




(95% CI) n NPV
Spec
(95% CI) n PPV
Spec








61 68.9 57.2 80.5 535 93.6 91.6 95.7 76 55.3 44.1 66.4 520 96.3 94.7 98.0 596




88 68.2 58.5 77.9 482 94.8 92.8 96.8 85 70.6 60.9 80.3 485 94.2 92.2 96.3 570




39 71.8 57.7 85.9 195 89.2 84.9 93.6 49 57.1 43.3 71.0 185 94.1 90.6 97.5 234




110 72.7 64.4 81.1 980 95.6 94.3 96.9 123 65.0 56.6 73.5 967 96.9 95.8 98.0 1090




0 n/a n/a n/a 8 87.5 64.6 100 1 0.0 0.0 0.0 7 100 100 100 8*




22 50.0 29.1 70.9 122 95.9 92.4 99.4 16 68.8 46.0 91.5 128 91.4 86.6 96.3 144




24 91.7 80.6 100 134 92.5 88.1 97.0 32 68.8 52.7 84.8 126 98.4 96.2 100 158




2 50.0 0.0 100 14 85.7 67.4 100 3 33.3 20.0 86.7 13 92.3 77.8 100 16*
66.3) % in Kisii to 91.7%  (95% CI: 80.6 - 100) % in 
Nyahururu.   
 Specificity was generally not statistically 
significant different within the study sites with the 
lowest observed in Kisii-Keroka (92.5%  (95%  CI:  88.1 
- 97.0) %). 
 Due to the small number of enrolled patients, 
especially in Wajir and Lamu, sensitivity and specificity 
of FM microscopy was estimated with wider confidence 
intervals. Therefore, with reduced precision. 
Key: *Sample size inadequate,  95% CI: Confidence Interval,          Sen:  Sensitivity,     Spec: Specificity,
 PPV: Positive Predictive Value,   NPV: Negative Predictive Value,     n: Number,     N: Total number
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(95% CI) n PPV (95% CI) n
NPV
(95% CI) N
Busia GeneXpert: site 21 85.7 70.7 100 141 87.9 82.6 93.3 35 51.4 34.9 68.0 127 97.6 95.0 100 162
Busia GeneXpert: KEMRI 21 85.7 70.7 100 141 88.7 83.4 93.9 34 52.9 36.2 69.7 128 97.7 95.0 100 162
Kitale GeneXpert: site 59 94.9 89.3 100 309 88.7 85.1 92.2 91 61.5 51.5 71.5 277 98.9 97.7 100 368
Kitale GeneXpert: KEMRI 59 93.2 86.8 100 309 90.0 86.6 93.3 86 64.0 53.8 74.1 282 98.6 97.2 100 368
Machakos * GeneXpert: site 3 100 100 100 45 80.0 68.3 91.7 12 25.0 0.5 49.5 36 100 100 100 48*
Machakos * GeneXpert: KEMRI 3 100 100 100 45 75.6 63.0 88.1 14 21.4 0.0 42.9 34 100 100 100 48*
Malindi * GeneXpert: site 3 66.7 13.3 100 35 91.4 82.2 100 5 40.0 0.0 82.9 33 97.0 91.1 100 38*
Malindi * GeneXpert: KEMRI 3 66.7 13.3 100 35 94.3 86.6 100 4 50.0 1.0 99.0 34 97.1 91.4 100 38*
Wajir * GeneXpert: site 4 0.0 0.0 0.0 40 85.0 73.9 96.1 6 0.0 0.0 0.0 38 89.5 79.7 99.2 44*
Wajir * GeneXpert: KEMRI 4 0.0 0.0 0.0 40 85.0 73.9 96.1 6 0.0 0.0 0.0 38 89.5 79.7 99.2 44*
 Table 10 shows performance of GeneXpert at 
study sites and KEMRI laboratory. The Sensitivity 
of GeneXpert at study sites ranged from 66.7%  (95% 
CI: 13.3 - 100.0) % in Malindi to 94.9%  (95%  CI: 
70.7 - 100) % in Kitale. Specificity was generally 
comparable with the lowest observed in Machakos 
(75.6%  (95%  CI:  63.0  -  88.1) %). 
 However, due to the small number of specimens 
analyzed using GeneXpert at both study sites and 
KEMRI, especially in Wajir, Malindi and Machakos, the 
sensitivity and specificity of GeneXpert was estimated 
with wider confidence intervals, in this case, with 
reduced precision.
Key:  95% CI: Confidence Interval,             Sen: Sensitivity,                        Spec: Specificity,      N: Total number 
      PPV:  Positive Predictive Value,    NPV: Negative Predictive Value,                n:  Number,  
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Discussion
 This study the first to document comparison on 
reproducibility of laboratory results and performance 
of the TB diagnostic tools in different geographical 
settings. Suggesting that, there was no statistically 
significant difference between reproducibility and 
performance of GeneXpert in all study sites including 
KEMRI. 
 This suggests that, under ideal conditions 
GeneXpert MTB/RIF is a reliable diagnostic tool 
irrespective of the facility setting. 
 Furthermore, the observations support the 
sentiments expressed in the WHO document on 
“Frequently Asked Questions on GeneXpert MTB/RIF 
assay” which indicates that the “new technology is a 
relatively low throughput technology and easy to use, 
it may be better suited at lower levels of the health care 
system (e.g. at County or Sub - County level). 
 Access to appropriate treatment for a case 
diagnosed with the new technology is also essential, 
and implementation of the new technology needs to 
be linked to treatment services” (www.who.int/tb/
labosratory/xrepert_faqs.pdf). 
 However, there are several pertinent factors 
that require redress prior to implementation of 
GeneXpert. These include adequate infrastructure 
without interrupted power supply, guranteed supply 
of cartridges, other potential consumables, frequent 
scheduled machine services such as maintenance and 
calibrations. 
 
 These factors if not adequately addressed 
and monitored could cause unnecessary delays in 
the diagnosis and subsequent mismanagement of TB 
patients.  
 Furthermore, the significantly lower specificity 
of GeneXpert than microscopy both at site and KEMRI, 
indicate that, microscopy could compliment GeneXpert. 
This is especially in settings with inadequate capacity 
including Infrastructure, Human Resource and High 
workload.  
 Generally, reproducibility of results for the ZN 
and FM microscopy varied across the sites but were not 
significantly different for GeneXpert. 
 The performance of ZN and FM in this study 
indicated that the results are consistent with those from 
a previous study conducted using the same population 
and it was shown that although sensitivity of FM 
was higher than that of ZN, the difference was not 
statistically significant [2] 
 Similar observations were made in a 
systematic review by Steingart KR, et al, 2006. The 
wider confidence intervals observed in sensitivity and 
specificity of GeneXpert observed in some study sites 
was mainly due to low numbers of samples involved 
in the analysis resulting in reduced precision in 
estimates. 
 There is need for continuous training in 
microscopy to enhance reproducibility of laboratory 
results and performance. 
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